12:00 AM
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PE0139: Phase I started

PhaseBio began a double-blind, placebo-controlled Phase I trial to evaluate single ascending-doses of subcutaneous PE0139 in about...

Read the full 65 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >